Jiasian W. Teh is a urologist based in Melbourne, VIC, Australia. He helps people with bladder, prostate, kidney and genital concerns, as well as some related health issues that often show up alongside urological problems. The focus is on clear advice, careful assessment, and getting a plan that fits the situation.
In day-to-day work, Dr Teh looks after patients with conditions like prostate cancer and kidney problems such as renal cell carcinoma (RCC). He also treats scrotal masses and urinary tract infections (UTI). Erectile dysfunction (ED) is another common reason people seek help, and it can affect confidence and day-to-day comfort, so support matters.
Some patients come in after surgery needs have been identified, including orchiectomy and prostatectomy. Others want help managing ongoing symptoms while tests are being arranged. At times, follow-up care is a big part of the job, especially when scans and pathology results guide the next steps.
While his main area is urology, the broader care he coordinates can include end-stage renal disease (ESRD) and penile cancer. These cases can be emotionally heavy, and it helps when the process is explained in plain language. In some situations, his work also overlaps with other conditions listed in his service range, such as Crohn’s disease, uterine fibroids, and lymphofollicular hyperplasia. That can be important when health issues are linked or when multiple doctors are involved.
Experience is built through managing a wide mix of referrals, urgent concerns, and longer-term treatment pathways. The aim is to keep things practical—what to do now, what to watch for, and what outcomes are realistic in each case.
Education details aren’t listed here, but the clinical approach reflects solid medical training and regular involvement with real patient care. If new treatment options, guidelines, or testing methods come up, Dr Teh will generally help patients understand what they mean and why they’re recommended.
Clinical trials aren’t specifically listed in the available details, so the focus stays on standard care and follow-up. Where research-led options are relevant, those can be discussed as part of the broader treatment conversation, based on each person’s circumstances.
